Simvastatin Therapy in Lymphocyte Cross-Match–Positive Kidney Transplantation Candidates

详细信息    查看全文

• 作者：U. Yakupoglu ; H. Kocak ; G.U. Karatas ; Y.K. Yakupoglu ; A. Dinckan ; N. Kececioglu ; A. Gurkan ; A. Demirbas ; O. Yegin and M. Tuncer
• 刊名：Transplantation Proceedings
• 出版年：2005
• 出版时间：2005
• 年：2005
• 卷：37
• 期：7
• 页码：2933-2935
• 全文大小：92 K

文摘

Objectives

Recent identification of several mechanisms by which statins decrease recruitment of monocytes and T cells into the arterial wall and inhibit both T-cell and B-cell activation and proliferation in vitro prompted us to study the immunomodulatory effects of statins. In this study, we examined the effect of simvastatin therapy on lymphocyte cross-match positivity in kidney transplantation candidates.

Methods

Simvastatin therapy (20 mg/d) was administered to 25 patients (18 men, 7 women of mean age 34 ± 11.7 years who displayed positive lymphocyte cross-matches between July 2002 and October 2004. The etiologies of end-stage renal disease were vesicoureteral reflux (n = 5), urinary stone disease (n = 4), glomerulonephritis (n = 6), amyloidosis secondary to familial Mediterranean fever (n = 1), and unknown (n = 9).

Results

The lymphocyte cross-match became negative in 10 patients 4–9 months, and successful kidney transplantation was performed in 6 of them. The serum creatinine levels of these patients ranged between 0.8 and 1.4 mg/dL. Two patients required higher doses, but none suffered from adverse effects. The remaining 4 patients are still undergoing pretransplantation evaluation.

Conclusion

Simvastatin therapy seems to be a cost-effective and useful method for lymphocyte cross-match–positive kidney transplantation candidates compared with immunoadsorption or intravenous immunoglobulin use.